Chiasma's oral ocreotide controls acromegaly in some patients

Chiasma is raising capital to fund a new drug application (NDA) submission to the US FDA for oral ocreotide in the treatment of acromegaly based on Phase III results that were published on 9 February in the Journal of Clinical Endocrinology and Metabolism (JCEM).